In vivo 9.4 Tesla MRI of a patient with drug-resistant epilepsy: Technical report - Takeaways - MDSpire

In vivo 9.4 Tesla MRI of a patient with drug-resistant epilepsy: Technical report

  • By

  • Rick H. G. J. van Lanen

  • Daniel Uher

  • Desmond H. Y. Tse

  • Esther Steijvers

  • Albert J. Colon

  • Jacobus F. A. Jansen

  • Gerhard S. Drenthen

  • Dimo Ivanov

  • Govert Hoogland

  • Kim Rijkers

  • Christianne M. Hoeberigs

  • Paul A. M. Hofman

  • Walter H. Backes

  • Olaf E. M. G. Schijns

  • January 16, 2025

  • 0 min

Share

  • 1

    Drug-resistant epilepsy affects 30-40% of patients with focal epilepsy, necessitating accurate diagnosis for effective surgical treatment.

  • 2

    Ultra-high field MRI at 9.4T shows promise in detecting epileptogenic lesions that are not visible on lower field strength MRIs.

  • 3

    The EpiUltraStudy aims to evaluate the impact of 7T and 9.4T MRI on lesion detection in surgical candidates with drug-resistant epilepsy.

  • 4

    9.4T MRI achieved a cubic spatial resolution of 0.6 mm, enhancing visualization of anatomical structures relevant for epilepsy diagnosis.

  • 5

    Despite challenges with magnetic field inhomogeneities, 9.4T MRI provides improved image quality and potential for better surgical outcomes.

Original Source(s)

Related Content